文献速递肿瘤 PET/CT

晚期胰腺癌姑息化疗期间瘤内代谢异质性时间变化的预测作用:前瞻性队列研究

Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study.
PubMed 文献 · J Nucl Med · 2019-06-14

该前瞻性队列研究纳入63例不可切除局部晚期或转移性胰腺癌患者,在一线姑息化疗前和首次疗效随访时行18F-FDG PET,分析原发胰腺肿瘤的SUV、体积参数和纹理特征。结果显示多数代谢异质性参数在化疗期间显著下降,且代谢异质性下降幅度在应答者中更明显,基线高compacity及SUVpeak和熵下降较小与较差PFS独立相关。

要点

  • 一线姑息化疗期间多数代谢异质性参数显著下降,应答者下降更明显。
  • 基线高compacity、SUVpeak下降较小和熵下降较小与较差PFS独立相关。
  • 高CA19-9、高基线SUVpeak和首次随访高变异系数与较差OS相关。

核心结论

  • 晚期胰腺癌患者姑息化疗期间代谢瘤内异质性降低与治疗应答相关,并可能预测PFS和OS。

研究设计与样本

  • 前瞻性队列研究,纳入63例不可切除局部晚期或转移性胰腺癌患者,在一线姑息化疗前和首次疗效随访时行18F-FDG PET。

主要发现

  • 63例患者最佳客观缓解率为25.8%(95%CI 14.6%-37.0%),中位PFS为7.1个月(95%CI 5.1-9.7个月),中位OS为10.1个月(95%CI 8.6-12.7个月)。
  • 多数代谢异质性参数在一线化疗期间显著变化,表现为瘤内异质性降低,且应答者下降幅度大于非应答者。
  • 多因素Cox回归显示基线高compacity(P=0.023)、SUVpeak下降较小(P=0.007)和熵灰度共生矩阵下降较小(P=0.033)与较差PFS独立相关。
  • 高CA19-9(P=0.042)、高基线SUVpeak(P=0.008)和首次随访高变异系数(P=0.04)与较差OS相关。

临床怎么用

  • 对晚期胰腺癌姑息化疗患者,可在基线和首次疗效随访时行18F-FDG PET纹理分析,动态评估代谢异质性变化以辅助预后判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic intratumoral heterogeneity (ITH) is known to be related to cancer treatment outcome. However, information on the temporal changes in metabolic ITH during chemotherapy and the correlations between metabolic changes and treatment outcomes in patients with pancreatic cancer is sparse. We aimed to analyze the temporal changes in metabolic ITH and the predictive role of its changes in advanced pancreatic cancer patients who underwent palliative chemotherapy. Methods: We prospectively enrolled patients with unresectable locally advanced or metastatic pancreatic cancer before first-line palliative chemotherapy. 18F-FDG PET was performed at baseline and at the first response follow-up. SUVs, volumetric parameters, and textural features of the primary pancreatic tumor were analyzed. Relationships between the parameters at baseline and first follow-up were assessed, as well as changes in the parameters with treatment response, progression-free survival (PFS), and overall survival (OS). Results: Among 63 enrolled patients, the best objective response rate was 25.8% (95% confidence interval [CI], 14.6%-37.0%). The median PFS and OS were 7.1 mo (95% CI, 5.1-9.7 mo) and 10.1 mo (95% CI, 8.6-12.7 mo), respectively. Most parameters changed significantly during the first-line chemotherapy, in a way of reducing ITH. Metabolic ITH was more profoundly reduced in responders than in nonresponders. Multiple Cox regression analysis identified high baseline compacity (P = 0.023) and smaller decreases in SUVpeak (P = 0.007) and entropy gray-level cooccurrence matrix (P = 0.033) to be independently associated with poor PFS. Patients with a high carbohydrate antigen 19-9 (P = 0.042), high pretreatment SUVpeak (P = 0.008), and high coefficient of variance at first follow-up (P = 0.04) showed worse OS. Conclusion: Reduction in metabolic ITH during palliative chemotherapy in advanced pancreatic cancer patients is associated with treatment response and might be predictive of PFS and OS.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Yoo SH, Kang SY, Cheon GJ, et al. Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study. J Nucl Med. 2019. PMID: 31201247. doi:10.2967/jnumed.119.226407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。